Biomarkers in Alzheimer’s disease: what can they really tell you?

Takeaway

  • The influence of cerebral spinal fluid (CSF) dynamics disorders such as high-convexity tight sulci (HCTS) may confound interpretation of amyloid and tau biomarkers in Alzheimer’s disease (AD) studies.

Why this matters

  • HCTS in the brain are a feature of a disproportionately enlarged subarachnoid space hydrocephalus (DESH). The HCTS distinguish DESH from other neurodegenerative disorders such as AD.

  • A clear understanding of HCTS is important to ensure correct classification in AD trials as HCTS may confound interpretation of clinical symptoms and biomarkers that define AD based on abnormal amyloid (A) and tau (T) biomarkers.